Adverse Events of BRAF and MEK Inhibitors

Video

Each type of cancer treatment has its own adverse event (AE) profile, and BRAF and MEK inhibitors are no different.

Each type of cancer treatment has its own adverse event (AE) profile, and BRAF and MEK inhibitors are no different, explained Michael A. Postow, MD, medical oncologist at Memorial Sloan Kettering Cancer Center.

In advanced melanoma, AEs may differ depending on the drug combination that a patient is prescribed. Those who are on dabrafenib (Tafinlar) and trametinib (Mekinist) are more likely to experience fever and chills. And if they do, it is important that providers hold treatment until these symptoms go away.

Patients prescribed vemurafenib (Zelboraf) plus cobimetinib (Cotellic) may be more likely to experience skin-related AEs, and need to be careful when it comes to sun exposure.

Finally, patients who take encorafenib (Braftovi) and binimetinib (Mektovi) may be more susceptible to arthralgia.

Recent Videos
Ann H. Partridge, MD, MPH, in an interview with Oncology Nursing News at 2024 ESMO Congress.
Elizabeth Burton in an interview with Oncology Nursing News
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.